Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNF&#945; therapy: a placebo-controlled phase II study.

Daien, Claire; Krogulec, Marek; Gineste, Paul; Steens, Jean-Marc; Desroys du Roure, Laurence; Biguenet, Sophie; Scherrer, Didier; Santo, Julien; Ehrlich, Hartmut; Durez, Patrick

Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: a placebo-controlled phase II study.

Daien, Claire; Krogulec, Marek; Gineste, Paul; Steens, Jean-Marc; Desroys du Roure, Laurence; Biguenet, Sophie; Scherrer, Didier; Santo, Julien; Ehrlich, Hartmut; Durez, Patrick.

Afiliação

Daien C; Montpellier University, CHU de Montpellier, Inserm U1046, CNRS UMR 9214, Montpellier, France c-daien@chu-montpellier.fr.
Krogulec M; NZOZ Lecznica MAK-MED S.C, Nadarzyn, Poland.
Gineste P; ABIVAX, Paris, France.
Steens JM; Medical Consultant, Brussels, Belgium.
Desroys du Roure L; ABIVAX, Paris, France.
Biguenet S; ABIVAX, Paris, France.
Scherrer D; ABIVAX, Montpellier, France.
Santo J; ABIVAX, Montpellier, France.
Ehrlich H; ABIVAX, Paris, France.
Durez P; Service de Rhumatologie, Cliniques universitaires Saint-Luc, Brussels, Belgium.

Ann Rheum Dis ; 2022 May 31.

Article em En | MEDLINE | ID: mdl-35641124

Palavras-chave

antirheumatic agents; arthritis, rheumatoid; methotrexate

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2022 Tipo de documento: Article